Brain insulin study aims to uncover why antipsychotics cause weight gain

NCT ID NCT03741478

Ongoing Knowledge-focused Sponsor: Centre for Addiction and Mental Health Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looks at how the antipsychotic drug olanzapine changes the way the brain responds to insulin, which may explain why these drugs often lead to weight gain and diabetes. Healthy volunteers will receive olanzapine or placebo, along with insulin nasal spray, and undergo tests of glucose metabolism and memory. The goal is to understand the brain's role in these side effects, not to treat any disease.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Olanzapine and intranasal insulin
What this could lead to: If successful, this study could clarify how antipsychotics cause metabolic side effects like weight gain and diabetes, potentially leading to safer treatments.
What could go wrong: This is a small, early-phase study in healthy volunteers, not patients. Results may not apply to people with mental illness, and the findings are exploratory.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY CONTROLS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEALTHY CONTROLS

Contacts and locations

Locations

Center for Addiction and Mental Health

Toronto, Ontario, M5T 1R8, Canada
University Health Network - Toronto General Hospital

Toronto, Ontario, M5G 2C4, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.